Screening and Treatment for Chlamydia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to offer free testing for chlamydia, gonorrhea, syphilis, and HIV. Participants who test positive can receive counseling and treatment options for themselves and their partners, also at no cost. The trial seeks to determine if this approach can lower chlamydia rates among women. It is particularly suited for Black or African American individuals, aged 15-26, living in Orleans Parish, who have had vaginal sex at least once.
As an unphased trial, this study provides a unique opportunity to access free testing and treatment, potentially improving personal and community health.
What prior data suggests that this screening is safe?
Research has shown that regular testing for sexually transmitted infections (STIs) like chlamydia, gonorrhea, syphilis, and HIV is generally safe and manageable. Health guidelines emphasize the importance of these tests for early infection detection. While specific data on negative effects from STI testing is lacking, the procedures are typically simple and non-invasive, using either urine samples or swabs.
Health authorities, such as the US Preventive Services Task Force (USPSTF), recommend regular screening, particularly for certain age groups and individuals at higher risk. This practice has been established for years and is considered a safe and effective method to detect infections early and prevent their spread. The low-risk nature of the screening process itself supports its safety for those considering participation in clinical trials involving STI testing.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores a new approach to reducing chlamydia infections. Unlike standard treatments that focus on treating individuals after they have been diagnosed, this trial emphasizes community-wide screening for chlamydia, gonorrhea, syphilis, and HIV. The idea is to catch and treat these infections early, potentially preventing their spread in the community. By proactively identifying and addressing these infections, researchers hope to significantly lower infection rates among women, leading to improved public health outcomes.
What evidence suggests that this screening is effective for reducing chlamydia rates?
This trial will focus on screening for chlamydia, gonorrhea, syphilis, and HIV. Research has shown that testing for these infections can help reduce their spread and impact. Many studies support the availability of reliable tests and treatments, particularly for chlamydia and gonorrhea. For instance, women tested for chlamydia had a 32% lower risk of developing pelvic inflammatory disease, a serious health issue. Studies also indicate that simultaneous testing for several STIs, including HIV and syphilis, can detect infections that might otherwise be missed. Overall, regular testing is crucial for early detection and successful treatment of these infections.14678
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Testing
Participants are tested for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost
Treatment
If positive, participants receive counseling and treatment options, including no cost expedited treatment
Rescreening
Participants have the option to be rescreened 3 months after treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Chlamydia, gonorrhea, syphilis, and HIV screening
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Community screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tulane University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Citations
Screening for sexually transmitted infections
... syphilis testing, and only 7 percent received repeat gonorrhea and chlamydia testing. ... screening for HIV, syphilis, genital chlamydia ...
Primary care screening for sexually transmitted infections in ...
We observed a substantial decline in testing rates for STIs from March-April 2020 (31% for chlamydia, 30% for gonorrhea, 23% for syphilis, 24% ...
Screening for Chlamydia and Gonorrhea: US Preventive ...
Accurate screening tests and effective antibiotic treatments are available for chlamydia and gonorrhea ... 56. Chlamydia, gonorrhea, and syphilis.
HIV and Syphilis Co-Screening Rates Among Patients Tested ...
This study found that a large proportion of patients tested for gonorrhea and chlamydia had missed opportunities for HIV and syphilis screening.
Determining the screening frequency for sexually ...
We included studies in the meta-analysis that described STI screening frequency and contained data on positivity for chlamydia, gonorrhea, and/or syphilis.
Recommendations for Providing Quality Sexually ...
The availability of screening tests are key for identifying gonorrhea, chlamydia, syphilis, hepatitis B, hepatitis C, HIV, trichomoniasis ...
Sexually transmitted infections (STIs)
WHO fact sheet on sexually transmitted diseases (STIs), providing information on the scope of the problem, prevention, diagnosis, treatment, ...
8.
cms.gov
cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=250&bc=AAAAAAAAIAAA&Screening for Sexually Transmitted Infections (STIs) and ...
The proportion of sexually active females between the ages of 15 and 25 screened for chlamydial infection annually is a quality measure by US health plans, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.